Table 1.
Basic characteristics of all of the pooled studies in the meta-analysis
| Study | Year | Country | Studydesign | TNM (7th edition) | Number of patients
|
Age (mean ± SD or range)
|
Gender (male/female)
|
|||
|---|---|---|---|---|---|---|---|---|---|---|
| SBRT/SABR | Surgery | SBRT/SABR | Surgery | SBRT/SABR | Surgery | |||||
| Wang et al12 | 2016 | People’s Republic of China | RS | T1N0M0 | 35 | 35 | 77.1±5.2 | 74.8±6.6 | 33/2 | 33/2 |
| Rosen et al11 | 2016 | USA | RS | T1/2aN0M0 | 1,781 | 1,781 | 75.5±9.1 | 74.8±7.8 | 1,014/767 | 1,004/777 |
| Ezer et al13 | 2015 | Canada and USA | RS | T1/2aN0M0 | 362 | 1,881 | 78±6.5 | 76±5.7 | 127/235 | 809/1,072 |
| Hamaji et al14 | 2015 | Japan | RS | T1/2aN0M0 | 41 | 41 | 73 (58–85) | 74 (61–86) | 31/10 | 32/9 |
| van den Berg et al15 | 2015 | the Netherlands | RS | T1/2aN0M0 | 197 | 143 | 77 (52–93) | 67 (40–84) | 143/54 | 96/47 |
| Chang et al16 | 2015 | USA | RCT | T1/2aN0M0 | 31 | 27 | 67.1 (43–82) | 66.7 (51–85) | 14/17 | 11/16 |
| Kastelijn et al17 | 2015 | the Netherlands | RS | T1/2N0M0 | 53 | 175 | 71.6±10.2 | 66.5±9.1 | 19/34 | 109/66 |
| Nakagawa et al18 | 2014 | Japan | RS | T1/2aN0M0 | 35 | 183 | 79.8±2.8 | 78.3±2.5 | 25/10 | 122/61 |
| Matsuo et al19 | 2014 | Japan | RS | T1/2aN0M0 | 53 | 53 | 76 (58–86) | 76 (50–88) | 42/11 | 37/16 |
| Port et al20 | 2014 | USA | RS | T1N0M0 | 23 | 76 | 76 (70–79) | 72 (66–77) | 12/11 | 26/50 |
| Crabtree et al5 | 2014 | USA | RS | T1/2aN0M0 | 56 | 56 | 70.0±8.1 | 70.7±10.6 | 29/27 | 32/24 |
| Verstegen et al6 | 2013 | the Netherlands | RS | T1-3N0M0 | 64 | 64 | 67.95±8.84 | 70.53±9.91 | 37/27 | 36/28 |
| Varlotto et al21 | 2013 | USA | RS | T1/2N0M0 | 137 | 180 | 73.3 (51–92) | 68.3 (38–87) | 66/71 | 99/81 |
| Palma et al7 | 2011 | the Netherlands | RS | T1/2N0M0 | 60 | 60 | 79 (76–81) | 79 (76–80) | 40/20 | 40/20 |
| Grills et al22 | 2010 | USA | RS | T1/2N0M0 | 58 | 69 | 74 (69–78) | 78 (55–89) | 22/36 | 28/41 |
Abbreviations: SD, standard deviation; SBRT, stereotactic body radiotherapy; SABR, stereotactic ablative radiotherapy; RS, retrospective study; RCT, randomized controlled trial; TNM, TNM classification of malignant tumors.